A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 1012
Summary
- Conditions
- Complete Response
- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- FIGO Stage III-IV
- Newly Diagnosed
- Partial Response
- Primary Peritoneal
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: Double-BlindPrimary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03522246
- Collaborators
- Bristol-Myers Squibb
- Gynecologic Oncology Group
- European Network of Gynaecological Oncological Trial Groups (ENGOT)
- Foundation Medicine
- Investigators
- Principal Investigator: Bradley Monk, MD, FACS, FACOG Lead Investigator and Coordinating Investigator for North America Principal Investigator: Rebecca Kristeleit, Bsc MBChB FRCP PhD Coordinating Investigator for Europe and the Middle East Principal Investigator: Keiichi Fujiwara, MD, PhD Lead Investigator for Asia
Get Well Soon